Is Exelixis Stock a Good Investment?

Exelixis Investment Advice

EXEL

To provide specific investment advice or recommendations on Exelixis stock, we recommend investors consider the following general factors when evaluating Exelixis. This will help you to make an informed decision on whether to include Exelixis in one of your diversified portfolios:

Examine Exelixis' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Exelixis' leadership team and their track record. Good management can help Exelixis navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Biotechnology space and any emerging trends that could impact Exelixis' business and its evolving consumer preferences.
Compare Exelixis' performance and market position to its competitors. Analyze how Exelixis is positioned in terms of product offerings, innovation, and market share.
Check if Exelixis pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Exelixis' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Exelixis stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Exelixis is a good investment.

Sell

Buy

Strong Buy

Our investment recommendation module complements current analysts and expert consensus on Exelixis. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time. To make sure Exelixis is not overpriced, please confirm all Exelixis fundamentals, including its ebitda, cash flow from operations, and the relationship between the price to book and total debt . Given that Exelixis has a price to earning of 48.17 X, we urge you to verify Exelixis market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Market Performance	Good	Details
Volatility	Very steady	Details
Hype Condition	Stale	Details
Current Valuation	Fairly Valued	Details
Odds Of Distress	Very Low	Details
Economic Sensitivity	Slowly supersedes the market	Details
Investor Sentiment	Alarmed	Details
Analyst Consensus	Buy	Details
Financial Strenth (F Score)	Strong	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine Exelixis Stock

Researching Exelixis' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 87.0% of the company shares are held by institutions such as insurance companies. The book value of Exelixis was currently reported as 7.43. The company has Price/Earnings To Growth (PEG) ratio of 2.26. Exelixis had not issued any dividends in recent years.

To determine if Exelixis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exelixis' research are outlined below:

	Exelixis has a strong financial position based on the latest SEC filings
	Over 87.0% of the company shares are held by institutions such as insurance companies
	Latest headline from zacks.com: Incyte Gears Up to Report Q3 Earnings Heres What You Should Know

Exelixis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exelixis. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exelixis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	6th of February 2024 Upcoming Quarterly Report	View
	14th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	6th of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Earnings surprises can significantly impact Exelixis' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Exelixis' investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2020-05-05	2020-03-31	0.13	0.15	0.02	15
2017-08-02	2017-06-30	0.04	0.06	0.02	50
2015-11-10	2015-09-30	-0.2	-0.22	-0.02	10
2001-02-28	2000-12-31	-0.2	-0.18	0.02	10
2021-05-06	2021-03-31	0.03	0.005	-0.025	83
2023-05-09	2023-03-31	0.15	0.12	-0.03	20
2023-02-07	2022-12-31	-0.12	-0.09	0.03	25
2022-08-09	2022-06-30	0.19	0.22	0.03	15

Exelixis Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Exelixis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Exelixis' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.

Buy

Most Exelixis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Exelixis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Exelixis, talking to its executives and customers, or listening to those companies' conference calls.

Macroaxis Advice Exposure Valuation

Exelixis Target Price Projection

Exelixis' current and average target prices are 28.83 and 25.76, respectively. The current price of Exelixis is the price at which Exelixis is currently trading. On the other hand, Exelixis' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Exelixis Market Quote on 23rd of October 2024

Low Price	28.38	Odds
High Price	29.03	Odds

28.83 Target Price

Analyst Consensus On Exelixis Target Price

Low Estimate	23.44	Odds
High Estimate	28.59	Odds

25.76

Historical

Lowest Forecast 23.44

Target Price 25.76

Highest Forecast 28.59

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Exelixis and the information provided on this page.

Exelixis Analyst Ratings

Exelixis' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Exelixis stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Exelixis' financials, market performance, and future outlook by experienced professionals. Exelixis' historical ratings below, therefore, can serve as a valuable tool for investors.

Know Exelixis' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Exelixis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exelixis backward and forwards among themselves. Exelixis' institutional investor refers to the entity that pools money to purchase Exelixis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Charles Schwab Investment Management Inc	2024-06-30	3.3 M
Aqr Capital Management Llc	2024-06-30	3.3 M
Norges Bank	2024-06-30	2.8 M
Bank Of New York Mellon Corp	2024-06-30	2.7 M
First Trust Advisors L.p.	2024-06-30	2.6 M
Jacobs Levy Equity Management, Inc.	2024-06-30	2.5 M
Fmr Inc	2024-06-30	2.3 M
Morgan Stanley - Brokerage Accounts	2024-06-30	2.3 M
Jupiter Asset Management Limited	2024-06-30	2.3 M
Blackrock Inc	2024-06-30	33.5 M
Vanguard Group Inc	2024-06-30	29.7 M

Note, although Exelixis' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Exelixis' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.22 B.

Market Cap

1.81 Billion

Exelixis' profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	0.09	0.10
Return On Capital Employed	0.13	0.13
Return On Assets	0.09	0.09
Return On Equity	0.10	0.10

The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.43 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.43.

Determining Exelixis' profitability involves analyzing its financial statements and using various financial metrics to determine if Exelixis is a good buy. For example, gross profit margin measures Exelixis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exelixis' profitability and make more informed investment decisions.

Exelixis' Earnings Breakdown by Geography

Evaluate Exelixis' management efficiency

Exelixis has return on total asset (ROA) of 0.0851 % which means that it generated a profit of $0.0851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1506 %, meaning that it created $0.1506 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Exelixis' Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.13 this year, although the value of Return On Equity will most likely fall to 0.10. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Intangibles To Total Assets will most likely fall to 0.02.

	Last Reported	Projected for Next Year
Book Value Per Share	7.02	7.37
Tangible Book Value Per Share	6.82	7.16
Enterprise Value Over EBITDA	18.00	18.90
Price Book Value Ratio	2.60	4.24
Enterprise Value Multiple	18.00	18.90
Price Fair Value	2.60	4.24
Enterprise Value	1.4 B	1.9 B

Exelixis benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.

Beta

0.541

Basic technical analysis of Exelixis Stock

As of the 23rd of October, Exelixis shows the Downside Deviation of 1.31, coefficient of variation of 599.96, and Mean Deviation of 1.44. Exelixis technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Exelixis treynor ratio, and the relationship between the standard deviation and downside variance to decide if Exelixis is priced favorably, providing market reflects its regular price of 28.83 per share. Given that Exelixis has jensen alpha of 0.3669, we urge you to verify Exelixis's prevailing market performance to make sure the company can sustain itself at a future point.

Exelixis' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exelixis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Michael Morrissey over two weeks ago Disposition of 480000 shares by Michael Morrissey of Exelixis at 24.41 subject to Rule 16b-3
		Hessekiel Jeffrey over three weeks ago Disposition of 25000 shares by Hessekiel Jeffrey of Exelixis at 26.38 subject to Rule 16b-3
		Christopher Senner over three months ago Disposition of 21862 shares by Christopher Senner of Exelixis at 22.86 subject to Rule 16b-3
		Wyszomierski Jack L over three months ago Disposition of 8287 shares by Wyszomierski Jack L of Exelixis at 22.0 subject to Rule 16b-3
		Johnson David Edward over three months ago Acquisition by Johnson David Edward of 42767 shares of Exelixis at 21.69 subject to Rule 16b-3
		Wyszomierski Jack L over three months ago Disposition of 11686 shares by Wyszomierski Jack L of Exelixis at 19.57 subject to Rule 16b-3
		Michael Morrissey over six months ago Disposition of 23304 shares by Michael Morrissey of Exelixis at 21.51 subject to Rule 16b-3
		Oliver Bob over six months ago Insider Trading
		Dana Aftab over six months ago Disposition of 10630 shares by Dana Aftab of Exelixis at 20. subject to Rule 16b-3
		Jack Wyszomierski over a year ago Exercise or conversion by Jack Wyszomierski of 15000 shares of Exelixis subject to Rule 16b-3
		Lance Willsey over a year ago Sale by Lance Willsey of 200 shares of Exelixis
		Wright Jacqueline over a year ago Acquisition by Wright Jacqueline of 20718 shares of Exelixis subject to Rule 16b-3

Exelixis' Outstanding Corporate Bonds

Exelixis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Exelixis uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Exelixis bonds can be classified according to their maturity, which is the date when Exelixis has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	EXELON P 495 Corp Bond US30161NAQ43	View
	EXELON P 395 Corp Bond US30161NAN12	View
	EXELON P 34 Corp Bond US30161NAU54	View
	EXELON P 51 Corp Bond US30161NAS09	View
	EXC 335 15 MAR 32 Corp Bond US30161NBE04	View
	EXELON PORATION Corp Bond US30161NAY76	View
	EXELON PORATION Corp Bond US30161NAX93	View
	EXELON P 445 Corp Bond US30161NAV38	View

View All Exelixis Corporate Bonds

Understand Exelixis' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Exelixis' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.1376
	Market Risk Adjusted Performance	1.7
	Mean Deviation	1.44
	Semi Deviation	0.9437
	Downside Deviation	1.31
	Coefficient Of Variation	599.96
	Standard Deviation	2.38
	Variance	5.65
	Information Ratio	0.127
	Jensen Alpha	0.3669
	Total Risk Alpha	0.1308
	Sortino Ratio	0.2312
	Treynor Ratio	1.69
	Maximum Drawdown	16.59
	Value At Risk	(2.09)
	Potential Upside	3.28
	Downside Variance	1.7
	Semi Variance	0.8905
	Expected Short fall	(1.82)
	Skewness	3.0
	Kurtosis	13.5

	Risk Adjusted Performance	0.1376
	Market Risk Adjusted Performance	1.7
	Mean Deviation	1.44
	Semi Deviation	0.9437
	Downside Deviation	1.31
	Coefficient Of Variation	599.96
	Standard Deviation	2.38
	Variance	5.65
	Information Ratio	0.127
	Jensen Alpha	0.3669
	Total Risk Alpha	0.1308
	Sortino Ratio	0.2312
	Treynor Ratio	1.69
	Maximum Drawdown	16.59
	Value At Risk	(2.09)
	Potential Upside	3.28
	Downside Variance	1.7
	Semi Variance	0.8905
	Expected Short fall	(1.82)
	Skewness	3.0
	Kurtosis	13.5

Consider Exelixis' intraday indicators

Exelixis intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Exelixis stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	38270.27
	Daily Balance Of Power	0.2615
	Rate Of Daily Change	1.01
	Day Median Price	28.71
	Day Typical Price	28.75
	Price Action Indicator	0.21
	Period Momentum Indicator	0.17
	Relative Strength Index	65.12

Exelixis Corporate Filings

8K	15th of October 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
F4	3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F3	8th of May 2024 An amendment to the original Schedule 13D filing	View Verify

Exelixis time-series forecasting models is one of many Exelixis' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Exelixis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Exelixis Stock media impact

Far too much social signal, news, headlines, and media speculation about Exelixis that are available to investors today. That information is available publicly through Exelixis media outlets and privately through word of mouth or via Exelixis internal channels. However, regardless of the origin, that massive amount of Exelixis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Exelixis news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Exelixis relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Exelixis' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Exelixis alpha.

Exelixis Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Exelixis can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Exelixis Historical Investor Sentiment

Investor biases related to Exelixis' public news can be used to forecast risks associated with an investment in Exelixis. The trend in average sentiment can be used to explain how an investor holding Exelixis can time the market purely based on public headlines and social activities around Exelixis. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Exelixis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Exelixis and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Exelixis news discussions. The higher the estimate score, the more favorable the investor's outlook on Exelixis.

Exelixis Corporate Management

Amy MD	Product VP	Profile
Laura Dillard	Executive Resources	Profile
Gregg Bernier	VP Marketing	Profile
William MD	Senior Affairs	Profile

When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports: